Form 4: Pharvaris Director Sells Shares Under 10b5-1 Plan

Pharvaris N.V. Director Johannes Schikan sold a total of 37,590 shares of common stock across two transactions on June 29 and June 30, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• Johannes Schikan, a Director at Pharvaris N.V., executed sales of company stock on June 29 and June 30, 2026.
• On June 29, 2026, 6,888 shares were sold at a weighted average price of $35.0533, with individual transaction prices ranging from $35.00 to $35.10.
• On June 30, 2026, an additional 30,712 shares were sold at a weighted average price of $35.4926, with individual transaction prices ranging from $35.00 to $35.90.
• These sales were conducted as part of a Rule 10b5-1 trading plan, indicating they were pre-scheduled.
• Following these transactions, Mr. Schikan beneficially owns 315,167 shares of Pharvaris N.V. common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider selling can be a negative signal, the execution under a 10b5-1 plan mitigates concerns about non-public information and suggests a pre-determined strategy.

Positives

• The sales were executed under a Rule 10b5-1 trading plan, which is designed to provide an affirmative defense against allegations of insider trading by establishing a predetermined plan for stock transactions.
• The reporting person has committed to providing full information regarding the number of shares sold at each separate price upon request.

Negatives

• A significant number of shares were sold by a company director, which could be perceived negatively by the market, despite being part of a pre-planned strategy.

Risks

• While the sales are part of a 10b5-1 plan, significant selling by insiders can sometimes lead to negative market sentiment or speculation about the insider's confidence in the company's future performance.
• The broad range of sale prices in the June 30 transaction ($35.00 to $35.90) might indicate market volatility or specific trading strategies employed within the plan.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it solely reports on past transactions.

Management Comments

• The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, is a common event for publicly traded companies. The significance of this particular sale depends on the director's overall holdings and the company's current valuation and growth prospects within the biotechnology sector.

Stakeholder Impact

• Shareholders: May interpret the director's sale as a signal, potentially impacting short-term stock price sentiment, though the 10b5-1 plan provides a mitigating factor.
• Management: The sale is a routine transaction for a director managing personal finances and diversification.
• Employees: Similar to shareholders, employees with stock options or holdings may observe this transaction.

Next Steps

• The reporting person may continue to execute transactions under the existing 10b5-1 plan.
• The company may provide further updates on insider holdings or transactions in subsequent filings.

Key Dates

Keywords

Pharvaris N.V., PHVS, Form 4, Insider Trading, 10b5-1 Plan, Stock Sale, Director, Beneficial Ownership, Securities Exchange Act